Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- MOH -19.9%, RBBN -14.5%, STM -8%, AN -7.9%, IBM -7.3%, OII -6.9%, VRE -6.7%, PKG -6%, SMPL -5.4%, ASGN -4.7%, WH -4.3%, ROP -4.2%, URI -3.8%, TSLA -3.5%, KNX -3.5%, ORI -3.4%, IRDM -3.1%, HXL -3% (also $350 mln accelerated share repurchase program), EEFT -3%, WFG -2.9%, HAS -2.7%, TMUS -2.7%, TSCO -2.5%, SAP -2.2%, LNN -2.2%, SIGI -2.1%, ELS -1.7%, TXT -1.4%, AUB -1.4%, TCBI -1.3%, CNP -1.3%, LRCX -1.2%, PLXS -1.1%, SAH -1.1%, IHG -1%, ORLY -0.8%
Other news:
- TBN -10.3% (prices offering of 2,324,445 shares of common stock at $21.00 per share)
- MRNA -4.4% (announces phase 3 study of mRNA-1647)
- HCM -1.5% (highlights HMPL-A251 data presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics)
- TXT -1.4% (names new CEO and Chair)
- APPS -1.1% (stock offering by selling shareholders)
- VOYA -0.7% (reports September AUM)
Analyst comments:
- SEAT -2.5% (downgraded to Neutral from Buy at Citigroup)
- ENPH -1.6% (downgraded to Neutral from Outperform at Mizuho)